Ignite Creation Date:
2024-10-25 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06651580
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-18
Brief Title:
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients INSPPIRE 2 Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Pediatric Longitudinal Cohort Study of Chronic Pancreatitis INSPPIRE 2
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial collects blood saliva urine or stool samples to help identify possible genetic mutations that may increase a persons chance at developing pancreatic cancer Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer
Detailed Description:
PRIMARY OBJECTIVE
I To comprehensively characterize the pediatric population with acute recurrent pancreatitis ARP and chronic pancreatitis CP and determine predictors of early onset CP and its sequelae
OUTLINE
Patients complete quality-of-life QoL assessment and complete questionnaires for over 2 hours every 12 months for 4 years Patients also undergo collection of blood andor saliva if blood samples are not available urine or stool at baseline or follow-up if inadequate samples collected or missed at baseline
After completion of the study patients are followed up every 12 months
I To comprehensively characterize the pediatric population with acute recurrent pancreatitis ARP and chronic pancreatitis CP and determine predictors of early onset CP and its sequelae
OUTLINE
Patients complete quality-of-life QoL assessment and complete questionnaires for over 2 hours every 12 months for 4 years Patients also undergo collection of blood andor saliva if blood samples are not available urine or stool at baseline or follow-up if inadequate samples collected or missed at baseline
After completion of the study patients are followed up every 12 months
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: